Phosphodiesterase 4 inhibitors for the treatment of COPD

Chest

Volumn 121, Issue 5, 2002, Pages 192S-196S

  Sturton, Graham ^a   Fitzgerald, Mary ^a  

^a Bayer plc Pharma Research   (United Kingdom)

Author keywords

BAY 19 8004; Cilomilast; COPD; Inhibitor; Phosphodiesterase; Roflumilast; Tobacco smoke

Indexed keywords

BAY 19 8004; CILOMILAST; CYCLIC AMP; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST;

ASTHMA; BIOAVAILABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG SELECTIVITY; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY CELL; LONG TERM CARE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE; SPECTRUM; VOMITING;

AMINOPYRIDINES; ANIMALS; BENZAMIDES; BRONCHODILATOR AGENTS; CARBOXYLIC ACIDS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYCLOPROPANES; HUMANS; NITRILES; PHOSPHODIESTERASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 0036264724     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.5_suppl.192S     Document Type: Article

References (23)

1. Structural and inflammatory changes in COPD: A comparison with asthma
2. PEUROSCOP, ISOLDE and the Copenhagen city lung study
3. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European respiratory society study on chronic obstructive pulmonary disease
4. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
5. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
6. Effect of fluticasone propionate on induced sputum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with COPD
7. Phosphodiesterase (PDE) 4 inhibitors: Anti-inflammatory drugs of the future?
8. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
9. Prostagladin E2 inhibits apoptosis in human neutrophilic polymorphonuclear leukocytes: Role of intracellular cyclic AMP levels
10. Inhibition of tumour necrosis factor-alpha induced neutrophil apoptosis by cyclic AMP: Involvement of caspase cascade
11. Ariflo (SB 207499), a second generation oral PDE4 inhibitor, improves quality of life in patients with COPD
12. The efficacy of Ariflo (SB 207499), a second generation oral PDE4 inhibitor, in patients with COPD
13. Acute anti-inflammatory effect of the novel phosphodiesterase inhibitor roflumilast on allergen challenge in asthmatics after a single dose
14. The therapeutic activity of SB 207499 (Ariflo™), a second generation phosphodiesterase 4 (PDE4) inhibitor, is equivalent to that of prednisolone in models of pulmonary inflammation
15. Emphysematous lung destruction by cigarette smoke: Effect of latent adenovirus 5 infection and retinoic acid treatment
16. Clinical effects of the neurotropic selective cyclic AMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports
17. The safety and tolerability of Ariflo™ (SB 207499), a novel selective phosphodiesterase 4 inhibitor, in healthy male volunteers
18. Biarycarboxylic acids and amides: Inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret
19. Phosphodiesterase 4: Biological underpinnings for the design of improved inhibitors
20. Safety and efficacy of the new PDE4 inhibitor roflumilast administered to patients with exercise-induced asthma over 4 weeks
21. Nicotinamide derivatives as selective inhibitors of PDE4
22. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B
23. AWD 12-343, a new orally active PDE4 inhibitor: Synthesis and comparison with SB 207499; rolipram and AWD 12-281